A comprehensive Cochrane review of 17 studies with over 20,000 participants finds that anti-amyloid Alzheimer’s drugs yield only trivial cognitive and dementia improvements after about 18 months, with benefits not meaningfully felt by patients or caregivers.

Drugs such as Lecanemab and Donanemab show little to no clinically meaningful benefit in early-stage Alzheimer's, while carrying higher risks of brain swelling and bleeds.

critics contend that pooling older, ineffective trials with newer ones may bias conclusions, though proponents argue that all trials share the same amyloid-removal target.

Public health implications loom large: treatment costs run roughly £50,000–£80,000 per person annually and regular MRI monitoring is required, shaping NHS adoption and planning for future therapies.

In the EU and Germany, reimbursement and market access decisions by bodies like the G-BA and the GKV-Spitzenverband influence whether manufacturers continue marketing these therapies.

Regulatory bodies such as NICE have questioned cost-effectiveness given uncertain and modest clinical benefits, impacting policy and coverage decisions.

Regulatory approvals for aducanumab and donanemab are controversial, with calls for longer follow-up and more diverse populations in future research.

German and other regulators echo skepticism about added clinical value, aligning with findings that these antibodies do not outperform symptom-focused or older treatments in practice.

Researchers emphasize that observed effects are too small for real-world notice and note a heavy treatment burden from visits, infusions, and MRI monitoring.

The 18-month window is acknowledged as short for a slowly progressing disease, and real-world use could involve longer treatment, potentially shifting risk-benefit calculations.

Clinicians and charities urge nuance, noting that some analyses mix failed trials with newer ones and that individual drugs may differ in effect, warranting cautious interpretation.

Some experts caution against broad dismissal of anti-amyloid therapies, pointing to methodological limits and the existence of drugs with different mechanisms not covered by this review.